Monte Rosa Therapeutics Surges on New Novartis Collaboration

Monte Rosa Therapeutics shares are trading higher after announcing a collaboration with Novartis to develop novel degraders for immune-mediated diseases, including a $120 million upfront payment with potential payments up to $5.7 billion.